ONO Pharmaceutical Reports 9.4% Drop in Sales and 33% Decrease in Net Profit for Fiscal Year Ended March 2025, EPS Falls to ¥218.02
Ono Pharmaceutical Co., Ltd. reported a 9.4% drop in sales to ¥451.8 billion and a 33% decrease in net profit to ¥102.4 billion for the fiscal year ending March 31, 2025. The decline was attributed to reduced drug prices, lower royalty revenue from Merck, and the absence of a previous year's lump-sum income from a patent settlement. Operating profit fell by 39% to ¥114.7 billion, while ordinary profit decreased by 40.3% to ¥112.3 billion, impacted by expenses related to FORXIGA Tablets and licensing agreements.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, has released its non-consolidated financial results for the fiscal year ended March 31, 2025. The company reported sales of ¥451.8 billion, marking a decrease of ¥47.0 billion, or 9.4%, compared to the previous fiscal year. This decline was primarily attributed to the revision of the National Health Insurance drug price for OPDIVO Intravenous Infusion for malignant tumors, a reduction in royalty revenue from Merck & Co., Inc. due to decreased royalty rates, and the absence of a ¥17.0 billion lump-sum income recorded in the previous year associated with a patent litigation settlement with AstraZeneca UK Limited. The operating profit for the fiscal year was ¥114.7 billion, down ¥73.2 billion, or 39.0%, year on year. Ordinary profit was reported at ¥112.3 billion, a decrease of ¥75.8 billion, or 40.3%. Net profit for the year was ¥102.4 billion, which represents a decline of ¥50.5 billion, or 33.0%. The financial performance was further impacted by the recording of a sales milestone of ¥13.6 billion for FORXIGA Tablets as an expense. These tablets are sold under a co-promotion agreement with AstraZeneca UK Limited. Additionally, expenses related to a licensing agreement with LigaChem Biosciences, Inc. contributed to the decrease in profits. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on May 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
